From selection hits to clinical leads: progress in aptamer discovery

Keith E. Maier, Matthew Levy

Research output: Contribution to journalReview articlepeer-review

70 Scopus citations


Aptamers were discovered more than 25 years ago, yet only one has been approved by the US Food and Drug Administration to date. With some noteworthy advances in their chemical design and the enzymes we use to make them, aptamers and aptamer-based therapeutics have seen a resurgence in interest. New aptamer drugs are being approved for clinical evaluation, and it is certain that we will see increasingly more aptamers and aptamer-like drugs in the future. In this review, we will discuss the production of aptamers with an emphasis on the advances and modifications that enabled early aptamers to succeed in clinical trials as well as those that are likely to be important for future generations of these drugs.

Original languageEnglish (US)
Pages (from-to)16014
Number of pages1
JournalMolecular Therapy - Methods and Clinical Development
StatePublished - Mar 16 2016

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics


Dive into the research topics of 'From selection hits to clinical leads: progress in aptamer discovery'. Together they form a unique fingerprint.

Cite this